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c-myc is a key regulator of hemopoietic stem cell (HSC) activity. In this issue of Cell Stem Cell, Laurenti et al.
(2008) show that c-myc and N-myc control HSC survival and link this finding to the regulation of granzyme B
expression.The human and mouse genomes include
three different myc genes, two of which
(N-myc and c-myc) appear functionally re-
dundant in mouse development, cellular
proliferation, and differentiation. A large
proportion of human tumors exhibit MYC
overexpression, and suppression of these
elevatedMYC levels is associated with re-
gression of tumor phenotypes. Recent
studies further indicate that ras-induced
tumors are dependent on MYC activity
(Soucek et al., 2008). MYC family proteins
are transcription factors that regulate
several cellular processes, including pro-
liferation, apoptosis, differentiation, and
growth. In addition to their typical role in
transcriptional regulation, MYC proteins
directly regulate translation of selective
mRNA (e.g., cyclinT1 and CDK9) by driv-
ing their cap methylation. MYC also binds
to the prereplication complex and local-
izes to sites of DNA replication (reviewed
in Cole and Cowling, 2008). High expres-
sion levels of MYC seem to correlate with
a greater number of active replication
origins, potentially explaining the active
DNA damage response and genomic in-
stability inMYC overexpressing cells.
c-mycmutant mice were described 6 to
7 years ago. Homozygous null mice expe-
rience midgestation lethality, and mutant
embryos display severe hemopoietic de-
fects. Homozygous null N-myc mutant
mice are also embryonic lethal and pres-
ent with neuroectodermal and heart de-
fects. L-myc, on the other hand, is nones-
sential. Conditional inactivation of c-mycwas reported by two groups, including
those of Trumpp (Wilson et al., 2004)
and de Alboran (Baena et al., 2007). Fol-
lowing induction of the Cre recombinase
in primitive and mature blood cells, c-myc
deletion (c-mycD/D) resulted in severe
depletion of progenitor cells and cytope-
nia leading to compromised survival of
several mice within 1 to 3 months. While
c-myc did influence the proliferation of
mature lineage marker-positive cells
(only 42% of c-mycD/D cells were in cycle
versus 95% of wild-type populations), it
was most intriguing that in both studies,
phenotypically primitive bone marrow
cells accumulated in 2- to 3-month-old
c-mycD/D mice. Neither reduction in apo-
ptosis nor increased cell proliferation ap-
peared responsible for this phenotype.
An alternate explanation, that c-mycD/D
hemopoietic stem cells (HSCs) increased
in number as a secondary response to se-
vere cytopenia, was consistent with the
observation that mutant HSCs appeared
activated (i.e., they expressed CD34 and
exhibited low levels of surface c-kit ex-
pression). In at least one of these studies,
c-mycD/D HSCs expressed much higher
levels of N-myc, raising the possibility
that functional redundancy disguised the
full extent to which HSC activity depends
on MYC. Overall, conditional deletion of
c-myc suggested that the impact of
MYC family proteins differed across prim-
itive and mature blood cell populations,
but the specificity of these effects re-
mained undetermined.Cell Stem Cell 3,In this issue, Trumpp and collaborators
present a comprehensive study that de-
scribes a striking blood phenotype in
compound c-myc and N-myc mutant
mice, in that loss of both MYC proteins re-
sulted in rapid lethality (Laurenti et al.,
2008). Indeed, Cre-induced deletion of
both genes is accompanied with acute
bone marrow failure (12–16 days), similar
to what was recently reported with a con-
ditional apc allele (Qian et al., 2008) and
considerably faster than that observed
with individual loss of c-myc (months) or
N-myc (no lethality). In the current study,
the authors first showed that primitive
HSCs express equal levels of both myc
genes, whereas c-myc is predominantly
expressed in more mature blood cells.
The authors then used this ‘‘state of the
art’’ dual conditional deletion paradigm
to study the impact of myc loss on HSC
function in either the context of acute
stress (severe cytopenia) or in a more
homeostatic condition in which the pres-
ence of chimeric control cells were
sufficient to maintain hematopoiesis. In
the first scenario, the effect of simulta-
neous deletion of both myc genes was
studied in compoundMx-Cre/N/c-mycD/D
(referred to as dmycD/D for double myc
mutant mice). In this case, a higher pro-
portion of cycling and apoptotic HSCs
was observed in dmycD/D mice than in
controls as early as 4–6 days following
Cre induction. Using a very elegant
in vivo labeling approach, the authors
also showed that myc is most critical forDecember 4, 2008 ª2008 Elsevier Inc. 579
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in G0) and that proliferating HSCs (prela-
beled with BrdU) are much less affected
by myc deletion. In a second approach,
the authors examined the impact of myc
deletion on mutant HSCs in the absence
of selective pressures exerted by acute
bone marrow failure. In this case, stable,
mixed hematopoietic chimeras were es-
tablished in normal irradiated recipients,
and thus upon dmycD/D ablation, wild-
type donor cells compensate and main-
tain essentially homeostatic blood cell
production. In the absence of severe
cytopenia, dmycD/D HSC still undergo ap-
optosis but at a much lower rate than in
nonchimeric animals. Intriguingly, in this
homeostatic context, dmycD/D HSCs
proliferated less than control cells, sug-
gesting that myc may be important for
the proliferation of HSCs, specifically
within ‘‘steady-state’’ conditions. The au-
thors propose that, in acute stress condi-
tions, in contrast, such as that observed
in acutely pancytopenic mice, the re-
quirement for myc in HSC proliferation is
overcome.
In addition to revealing that HSC activ-
ity appears to require a threshold of
MYC family protein, Laurenti et al. also
shed light on the critical antiapoptotic
function of MYC in the most primitive
HSC subset. In particular, the finding
that Granzyme B (GrB) is profoundly
(over 2 logs) upregulated in dmycD/D
HSCs is most novel. GrB is a serine prote-
ase and a main component of exocytic
granules used by cytotoxic T cells (CTL)
and natural killer (NK) cells to destroy in-
fected or transformed cells, but, to date,
GrB has not been detected in other blood
cell lineages. The use of GrB to kill multi-
ple target cells in succession puts NK
and CTLs at risk for self-inflicted damage,
and thus, these cell types express a cyto-
solic protein, Serine Protease Inhibitor 6
(Spi6), for their own protection. Notably,
the small proportion of CTLs that possess580 Cell Stem Cell 3, December 4, 2008 ª20long-term self-renewal potential, memory
CTLs, do not express GrB. It has been
proposed that CTLs, like adult HSCs, un-
dergo asymmetrical division and that GrB
segregates to the short-lived effector-
fated daughter CTL, as opposed to the
memory-fated daughter (Chang et al.,
2007).
Mice with deletion of GrB or Spi6 have
ostensibly normal hemopoiesis and lym-
phopoiesis, (Heusel et al., 1994; Zhang
et al., 2006); thus, the dramatic upregula-
tion of GrB specifically in dmycD/D HSCs
raises several intriguing questions. For
example, what is the mechanism of GrB
upregulation in HSCs? GrB is normally
undetectable in mouse and human
HSCs. However, it is upregulated in hu-
man CD34+ cells following administration
of chemotherapy and in SLAM-HSCs of
dmycD/D mice (Laurenti et al., 2008). To-
gether, these observations suggest that
GrB induction might follow activation of
some elusive stress signaling pathway in
HSCs. In line with this hypothesis, Lau-
renti et al. provided evidence that ribo-
some biogenesis is strongly inhibited in
dmycD/D HSCs. Nonetheless, the reason
whymyc depletion leads to GrB accumu-
lation solely in HSCs and not in more dif-
ferentiated cells is not inherently obvious.
In CTLs andNK cells, GrB is stored in exo-
cytic granules. However, Laurenti et al.
found thatmyc deficiency leads to diffuse
accumulation of GrB in the cytoplasm of
HSCs, rather than in a punctate, granular
pattern. How does GrB reach the cyto-
plasm in this population? Secreted GrB
can enter target cells after binding to the
mannose 6-phosphate-receptor; how-
ever, in the absence of perforin, GrB is
sequestered in endosomes and, thus, is
neither toxic for target cells nor for CTLs
themselves (Lord et al., 2003). Presum-
ably, perforin coordinates with GrB to
mediate effector CTL ‘‘suicide’’ by allow-
ing GrB leakage in the CTL cytoplasm.
Therefore, the striking observations from08 Elsevier Inc.Laurenti et al. suggest that either myc-
depleted HSCs cannot compartmentalize
GrB in exocytic granules or that GrB has
an unidentified partner allowing it to be
translocated from granules to the cyto-
plasm. These questions, as well as
whether and how GrB contributes to the
apoptotic process of dmycD/D HSCs, will
require additional experiments. Whether
GrB participates in the functional expan-
sion or deletion of HSC populations under
other situations of hematopoietic stress
also remains to be answered and will be
interesting to see addressed.
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